AI Agents for Divestiture and Spin-Off Analysis

I need to compare our results from the autonomous vehicle survey and the survey questionnaire against the attached 2025 launch targets. For these three metrics, calculate the percentage points gap between what we measured and our target: 1) What percentage of European respondents expect AVs to go mainstream within the next 5 years (inclusive of 5 years), compared to our Europe target? 2) What share of total global respondents would pay over $100 per month for AV subscriptions versus our $100+ tier target? 3) What is our high-trust percentage (scores of 4-5) compared to the consumer trust target? Please provide each answer as a reply to me in here, rounded to whole numbers.

Can you use the files on Deal Win Rate Target and the transaction history in Brightpath Deal Transactions to determine the Implied Deal Volume required to reach the Expansion target share of revenue for the 'Upper Mid-Market' segment? Apply the target expansion share from the Target Revenue Mix Strategy to the segment's total realized revenue in the deal transactions dataset (from "Won" deals only), to get the specific number of deals the sales team must close, based on the actual average size of an Upper Mid-Market Won expansion deal. Also, calculate the Required Pipeline Capacity for the 'Europe - Enterprise' sector, assuming the target ARR is equal to the sum of all "Won" deals in the Enterprise segment in Europe in the dataset, and assuming the sales team achieves the Target Win Rate for Europe Enterprise deals. Round numeric outputs to the nearest whole number and round currency outputs to the nearest dollar. Return your findings as a message to me here.

Using the REIT model, consider the following assumptions for the projected period between 2025 to 2029: 1) Assume the revenue growth for its service business equivalent to the overall company revenue growth 2) Assume that the EBITDA margin for the service business is 5 percentage points higher than the company EBITDA margin during the same forecast period 3) Assume depreciation equivalent to 2% of the annual revenues 4) Assume capex equal to 3% of the annual revenue 5) Assume investment in working capital equal to 1.5% of the annual revenue 6) Assume the effective tax rate is equal to 21% 7) Assume that the spin-off is done on a debt free, cash free basis 8) Assume the valuation date as of December 31, 2024 9) Assume a cost of equity of 12% and a terminal growth rate of 1% post the projected period. Compute the levered free cash flows and the implied equity value of its service business. Round all the values up to two decimals: - Cumulative Levered Free Cash Flows (2025 - 2029) - Terminal Value - Equity Value of the service business Reply here.

Using the State of Fashion Beauty report for 2024 sales and sub-category shares, alongside the attached data for Mass Market vs. Premium share by sub-category, calculate the difference (in $M) between the North American Mass Market and Premium segments for Skincare and Fragrance. Assume North American breakdowns by sub-category and segment match those of the global benchmarks. Report values as positive if Mass Market is larger and negative if Premium is larger. Using the data from the internal financials spreadsheet, determine Lumea's North American market share of the Premium segment of each sub-category (Skincare and Fragrance). Assume North American revenue percentages are uniform across all segments, all Lumea sales are Premium, and Lumea's Skin and Body units fall under Skincare. Round currency outputs to the nearest $0.1M and round percentage outputs to the nearest 0.1%. Provide your findings to me here in a reply.

Calculate the projected Operating Profit contribution ($ Millions) from the Europe Growth segment from updated growth bridge charts, assuming this new revenue achieves the 2030 Operating Margin target. Also, calculate the Total Incremental Gross Profit ($ Millions) generated by the combined International Expansion, assuming these new markets achieve the 2030 Gross Margin target. We need to use the results from the Lumea Financials Report and the updated Strategic Growth Bridge (attached) from the client. Output all financial values rounded to whole numbers (no decimals). Print your answers right in here.

Planet Fitness is looking to divest its entire 281 stores, which it owns as of September 30, 2025, to a franchise owner. Round all results to two decimal places and present it in $mm. Using the LBO model, perform a DCF analysis for the company as per the base case scenario for the projected cash flows for the 281 stores, and assume the following: 1) Assume that the average revenue per store increases by 5% YoY for every quarter from Q4 2025 through the end of 2030 2) Assume EBITDA margin for the business remains at 39% every quarter from Q4 2025 through the end of 2030 2) Assume that the effective tax rate is 20% 3) Assume that the depreciation rate is 5% of the revenue 4) Assume that maintenance capex is 2% of sales and there is no growth capex 5) Assume a discount rate of 12% and terminal growth rate of 2% 6) Do the enterprise valuation as of December 31, 2025 Print here the FCFF for 2026 to 2030. Also give the Enterprise Value of the corporate-owned store business

Planet Fitness is considering the acquisition of 100% stake in The Gym Group and taking it private in order to expand its presence within the UK. Using GYM H1 2025 and GYM annual 2024 docs, consider the following assumptions: 1) Assume the full year 2025 revenue equal to LTM revenue June 2025 2) Assume the full year 2025 Group Adjusted EBITDA less normalized rent equal to LTM Group Adjusted EBITDA less normalized rent June 2025. 3) Assume the annual revenue growth is 3% for all years going forward beginning January 1, 2026 4) Assume the annual margin expansion going forward beginning January 1, 2026 is 50 bps 5) Assume that GBP/USD exchange rate is equal to 1.31 as of December 31, 2025 and GBP will appreciate 2% every year beginning January 1, 2026 6) Assume that Depreciation and Amortization is 5% of the revenue and the existing debt at the end of June 30, 2025 is refinanced at a rate of 3.00% for an amortization term of 5 years based on equal payments. For interest expense computation, consider it based on the opening balance. 7) Assume that there is no other operating income or expenses and effective tax rate is 10%. 8) Assume there's no capex or change in NWC during the projection period. 9) Assume the 100% acquisition in The Gym Group is announced at 11x EV/ 2025 Group Adjusted EBITDA less normalized rent on December 31, 2025. 10) Assume the net debt as of June 30, 2025. 11) Assume that The Gym Group provides dividends to the parent on December 30 every year to a maximum of its Profit after tax. 12) Assume that the exit multiple at the end of December 31, 2030 is 12x EV / 2025 Group Adjusted EBITDA less normalized rent. 13) Assume that there is no interest income on cash during the projection period and no cash balance at the end of December 31, 2030. Return for me a message with the Equity Value for 100% stake purchase of The Gym Group. Also give me the 2026 to 2030 dividends, and the IRR for Planet Fitness (post FX conversion). In your answer, round the percentages and the millions to two decimal places.

Output the year 5 Equity Value to Sponsors and IRR (with a 5 year exit). From the existing LBO model, update values to both a 20% equity rollover from existing shareholders and a 10% management option pool. Write the information straight here. Assumptions: -Existing shareholders have agreed to roll 20% of their exit proceeds into the deal as a source of funds (i.e., note that existing shareholders will have a 20% pro forma equity stake) -Impact of net option dilution calculation as follows: *Options only trigger if exit equity is greater than entry equity *If options trigger, gross proceeds to management is total exit equity multiplied by the percentage of management's option pool *Netted against management's cost to exercise, calculated as the value of entry equity multiplied by percentage of management's option pool Round monetary values to nearest whole number. Round all other values to 1 decimal point.

What is the EV and implied share price of CNS in the DCF model using both Gordon growth model and exit multiple approach if each business segment grows as outlined below over the projection period of 2025 to 2030? Segment 1 - Investment advisory and administration fees grows at 7.0% revenue growth per annum Segment 2 - Distribution and service fees grows at 6.0% revenue growth per annum Segment 3 - Other grows at 5.0% revenue growth per annum Output the following to me with a short message in reply: 1. EV using the Gordon growth method 2. Implied share price using the Gordon growth method 3. EV using the exit multiple approach 4. Implied share price using the exit multiple approach Report share price in $ and to 2 decimal places, report EV in whole number and in millions. For operating expenses and capex use the Operating Assumptions (provided as a % of total revenue) laid out in the “LBO Model-hardcoded” tab.

From Becton Dickinson's FY2025 Annual Report assume the FDA finds that one violation regarding the Alaris SE infusion pumps, and decides the company is in violation, and enforces the consent decree on Alaris SE infusion pumps from November 29, 2024, to November 28, 2025, inclusive. Compute the average dollar burden of the penalty on BDX average shareholder. Output the result in USD as a reply to me here, rounded to 4 decimal places. Assume a 30-day month and a 360-day year.

In The Aptar Group's 2024 annual report, extract global revenue for the Pharma segment in 2023 and 2024. Compute the aggregate dollar change in thousands of USD adjusted for 7.1% 2024 global inflation and express the result in USD, rounded to the nearest thousand. Print back to me what you find please.

Using the 2024 annual report, identify whether Impact Therapeutics sells primarily branded drugs. A company sells primarily branded drugs if the majority of drugs have launch dates within the last 7 years. Please use the BCG report to determine the average COGS as a % of revenue for competitors in Impact Therapeutics' segment, based on whether they sell primarily generic drugs, branded, or a mix. Round to the nearest %. In both the global and US geos, state whether Impact Therapeutics is above the segment average calculated from the data in the BCG report. Write your response as a reply to me here.

Calculate and report the following metrics: 1. The Overall Vitamins Purchase Intent Score for each buyer segment. 2. The buyer segment with the highest average purchase intent score for Vitamins 3. The Vitamin Purchase Intent Index 4. Whether the Vitamin Purchase Intent Index Rating is desirable or undesirable Vitamin Purchase Intent Index is a composite metric calculated as: Average of Vitamins Purchase Intent Score across all segments × Segment Weight (i.e., Average of Population Size of buyer segment with highest purchase intent score for Vitamins × Average of Loyalty Score of buyer segment with highest purchase intent score for Vitamins) x PureLife Awareness Factor (i.e., Survey Respondents who said ‘Definitely yes’ or ‘Probably yes’ to trying PureLife divided by total Survey Respondents who have heard about PureLife). Vitamin Purchase Intent Index Rating is determined as: Vitamin Purchase Intent Index of >=8 is considered 'Desirable' other wise is considered 'Undesirable'. Base your analysis off the survey data and buyer behaviour data. Percentage values must be formatted to the nearest 0.01%. Dollar values must be formatted as US$ with 2 decimal places All other number calculations should be formatted to two decimals. Post your answer straight here.

Harborview has contemplated a new spinoff transaction as outlined in the attached memorandum prepared by the CLO. Review the memorandum and explain whether Alex Morgan will be subject to reporting requirements under 31 U.S.C. § 5336. You can reply right here with a short message please.

We need additional analysis for 2025 cost per activated member (CPAM) under 3 scenarios. I want you to edit the PnL workstream draft deck with this new information you'll calculate--> the 2025 CPAM ($ per activated member) for As reported, Profitable acquisition, and Industry normalized. Use the loyalty marketing memo for total 2025 CPAM and loyalty + reactivation spend, the PnL master profitability spreadsheets file for active and segment member volumes and segment , and the segment profitability assumptions spreadsheets file for segment level economics. Use marketing_benchmark.pdf for industry activation benchmarks. First, report the "as-reported CPAM" exactly as documented in the materials, corresponding to the 2025 full year projected CPAM. Second, calculate the "profitable acquisition CPAM" by focusing only on traveler segments that generate positive EBITDA per member. Allocate Summit's total 2025 loyalty and reactivation spend across segments based on each segment's share of total customer acquisition cost as calculated using the segment level numbers. Determine each segment's activated members using an assumed activation rate of 53%. Use loyalty and reactivation cost and active members to compute the the total cost per activated member across only profitable segments. Third, for the industry-normalized case, use the profitable segment scenario analysis and replace Summit's actual activation rate with the benchmark activation average from the industry data in marketing_benchmark.pdf. The benchmark activation average should include all competitors in the file and leverage midpoints for ranged values. Round all CPAM values to two decimal places for the final deck.

Using the accretion dilution model, produce the deliverables outlined below. Round all the figures to whole numbers, present monetary amounts in $ mm and display percentages to two decimals places. The client wants to make the following adjustments to the DCF model. - Revise the COGS assumptions for both Cost of Product & Cost of software and rentals as a % of Revenue, and make it a three-year moving average for 2025E and future years. For years 2026E, 2027E, 2028E and 2029E, add 25 basis points to each year's three-year moving average. Update the gross profit based on these assumptions - Revise the Selling, general and administrative expenses by making it a three-year moving average for 2025E and future years - Revise the Research and development expenses to 10% of sales for years 2026E through 2029E if prior years discounted cashflows exceed $1,000 mm and apply a three-year moving average for years where discounted cashflows are below $1,000 mm - Revise the revenue growth assumptions by changing 2025E growth to -0.5% for both Sales of Product & Sales of Software and Rentals. For years 2026E through 2029E, use a three year moving average for each year and subtract 50 basis points from that calculated growth rate each year - Use a WACC calculated by using only Zimmer Biomet and Smith & Nephew in WACC Calculation as comparables - Use a terminal growth rate of 1.5% Return a short message explaining to me: 1. Sum of Discounted Value of cashflows for 2025E through 2029E excluding the terminal value. 2. Terminal Value. 3. Discounted Terminal Value. 4. Enterprise Value 5. Discounted Terminal Value as a percentage of Enterprise Value.

Assume that no transaction happens with SOLV. Now, calculate the impact of a large investment in AI for MMM shareholders as an alternative capital allocation strategy using the accretion dilution model. Print me back the answer right here, showing: Total new debt from MMM's AI related initiatives Total debt Total after tax Interest Expense PF Net Income Pro Forma EPS EPS accretion/dilution Ending cash Using the following assumptions calculate the impact to EPS for MMM shareholders assuming no transaction with SOLV: - Required investment in technology of $5 billion - half of the investment to be financed from cash in hand and the rest with new debt at a 8.5% cost - Reduction in work force resulting cost savings pre tax of $1 billion - Severance cost associated with the reduction in work force of $4 billion to be financed with $500 million of cash in hand and the rest with new debt at a 12% cost. Assume 50% of the total severance costs will be paid upfront and the remainder over a 4 year period in equal amounts with the first payment beginning in year 1. These costs should be accounted as an expense and not capitalized. Any remaining cash from the debt not used upfront goes to the balance sheet - Increase in power costs associated with the investment in AI of $600 million per year - Apply an incremental 10% tax on power cost for every $100 million of power spend as a pollution compensation policy. Assume the 10% tax doubles for every $100 million of incremental spend. Assume this tax is embedded in the cost. - Assume to bolster balance sheet, MMM also issues equity for equivalent of $2 billion dollars at a issuing price of $250 dollars per share Remember in your answer: EPS should have two decimals. Percentages should have two decimals. All other values given as $ in millions, no decimals.

We want to do some historical analysis. Using stock prices for the 250 trading days up to Nov 19, 2025, calculate the beta for SOLVM to the XLV ETF. Then over the same time period, calculate the beta for MMM to the XLI ETF. Using the CAPM, calculate the cost of equity (Ke) for each company. Assume an expected market return of 12% and a risk-free rate of 3.95%. Print the answers back here. Use the accretion dilution model for stock prices for SOLV and MMM. Use the XLV Healthcare ETF and XLI Industrials ETF files for stock prices for the XLV and XLI ETFs. Use adjusted close prices. Present betas as a decimal, rounded to two decimal places. Present the cost of equity as a percentage, rounded to 1 decimal place.

In the Accretion / Dilution Model, use the capital structure and shares outstanding assumptions for Solventum (SOLV) to calculate levered free cash flow and price per share. Specifically, use the following incremental assumptions: - Revenue Growth Rate: 2.0% beginning in FY25E through the end of the forecast period FY29E - SOLV Interest Rate: 5.50% to forecast interest expense - Other expense (income), net: Remains $0.00 in each period - Cost of Equity: Use the average of cost of equity of the three comps used in the WACC calculation (Exclude Zimmer Biomet) - Capex: 110.0% of D&A beginning in FY25E through the end of the forecast period FY29E With all that, calculate the implied price per share to 2 decimal places. Reply straight back to me here.

Estimate impact to EPS of MMM divesting 1/3, 2/3 or 100% of its holdings in SOLV. Using the accretion dilution model, calculate the EPS impact of selling the different amounts of shares. Assume that MMM has to pay a 20% tax on the proceeds from the divestiture of the first 1/3 of the shares, a 25% tax on the next 1/3 and a 30% tax on the last 1/3 of the shares. Assume that net proceeds from the divestiture are invested in an instruments that pays an 8% interest rate upfront and that interest income is taxed at 35%. Tell me: 1- Percentage of SOLV Divested 2- EPS Accretion / Dilution 3- Pro forma net income Pro forma net income should incorporate the impact of investment of net proceeds from divestiture at 8% and after tax. All figures should be presented with two decimals. Output the final results by making a new Spreadsheet file.

Present all $ output values in million, round all output values to 1 decimal place. Get the following directly from the accretion dilution model: - Enterprise Value (DCF output) - PV of Free Cash Flows (2025–2029) - Terminal Free Cash Flow (2029) - Terminal Growth Rate (g) - WACC Assume that 3M ownership stake = 20% and: 1. Compute 3M’s stake value using the current DCF Enterprise Value. 2. Reduce each of the FCFs for 2025–2029 by 10% and recalculate the PV of those 5 cash flows using the 7.6% WACC. 3. Recalculate the Terminal Value using the reduced 2029 FCF but keeping the same 3% terminal growth rate and 7.6% WACC. 4. Combine the new PV(FCFs) and PV(TV) to estimate a downside Enterprise Value, and compute the implied downside stake value for 3M. 5. Calculate the percentage loss based on the implied stake values Present your findings in a new deck with: - 3M's Current Implied Stake Value - Sum of PV of Revised Discounted FCFs - Recalculated Terminal Value discounted to the Present - 3M's Revised Stake Value - Percentage Loss

Compare the average tenure of Solventum's board members to the average of its peers' board members (excluding Solventum). Give their average tenure. Then, state which is larger and by how many years. Use the data available in: BLCO DEF14A 2025, 5Form DEF 14A for GE Healthcare Technologies INC filed 04:10:202, PEN Form DEF 14A 2025, ZBH DEF14A 2025, and March 21, 2025 - DEF 14A SOLV. Print your answer back here. Follow these assumptions: 1. Solventum's peers and/or competitors are considered to be those companies listed in the comps folder 2. The competitor average is calculated using all director tenures individually, and not by averaging the averages of each company 3. Average tenure should be presented in years, rounded to 2 decimal place 4. If a member of a company's board of directors was a member prior to a spin-off of the company, the tenure starts on the year of the spinoff 5. Nominated board candidates that have not yet served are considered to have 0 years and 0 months of tenure 6. Tenure for each individual board member should be calculated based on filing date of the source doc and to the nearest year and month before subsequent calculations. Assume tenure began at the midpoint of the year/month stated if an exact date is not given.

Using the merger model and 0000066740-25-000089, please calculate: 1. The Number of Shares Repurchased. 2. The Revised Enterprise Value. 3. The Revised EV/EBITDA multiple for 3M. 4. The Revised P/E ratio for 3M. Present all monetary values in million dollars, rounded to nearest million. Round the number of shares, ratios and percentages to two decimal places. Print your reply back here as a short message. Assumptions and guidance for deliverables: - Note that debt to equity ratio for 3M as of end September 2025 can be calculated using 3M Total Equity in the other file. - Assume that 3M Share price dropped by 8% before the buyback and remained flat after that. - Assume that the amount of proceeds from sale of Solventum are used to paydown debt by 3M to bring debt to equity ratio down to 2.60x. - The left over proceeds from sale of Solventum after paying debt is used by 3M to repurchase shares. - Assume that EBITDA can be adjusted to 2025E EBITDA by multiplying it with 1.05 for simplicity. - For the enterprise value working, use the cash in tab "Assumptions S2". - For the Revised P/E ratio, use the TTM net income given in "Assumptions S2" tab.

Calculate the intrinsic value per share of Solventum based on these assumptions. Use the accretion dilution model. - Lower the gross margin % to 52% for the forecast period 2026E through 2029E. - Change Research & Development expenses as % of Sales to 15% wherein the discounted cashflow is higher than $1,100 mm in the preceding year, and to 10% wherein the discounted cashflow is lower than $1,100 mm in the preceding year for the years 2026E through 2029E. - Remove the comparable Koninklijke Philips from the WACC calculation. - Change the terminal growth rate to 2.0%. - Convert fixed CAPEX to a % of sales, and project using the last 3-year moving average to calculate it for the years 2025E through 2029E. - Update the discounting with 1/12 for 2025E, given that we are at the start of Dec 2025. Adjust the future years discounting convention accordingly. - Pull shares outstanding and Net debt from the "Assumptions S1" tab. Round the final deliverable to two decimal places and express in $ terms. Give me your response right here.

Evaluate the sensitivity of EPS impact to synergies and cost of new debt for the acquisition of SOLV by MMM using the accretion dilution model. Create a new tab in the file, with a table to show EPS impact (accretion or dilution). - Show synergies in increments of $300 million (300m, 600m). - Show cost of new debt in increments of 5ppts (15%, 20%). - Show the price premium per share at different synergy levels. - Assume the price premium per share is 25% for no synergies and increases by 2.5ppt every $100 million in synergies. - Two dec points only.

Under Scenario 1 in the Accretion / Dilution Model, 3M will use 50% debt / 50% equity. $250 million in pre-synergies were identified. Use the following assumptions in the Assumptions S1 tab of the Accretion / Dilution model: - Pre-Tax Synergies: $250mm - Control Premium: 25% - % Stock: 50% - % Debt: 50% - Interest Rate on New Debt: 8% - Fees: 1.5% of Updated Take-Private Enterprise Value - Solventum Share Price: Use the Solventum VWAP for the 75 trading days up to November 19, 2025. To calculate the price for each trading day in VWAP, use the formula (High + Low + Close) / 3 We need the Revised Accretion / Dilution percentage for 3M. Round percentages to 2 decimals points. Write back to me with your response now.

Perform a value-creation analysis based on scenario 1 using the accretion dilution model to assess whether Scenario 1 creates or destroys value for 3M Shareholders. Assumptions: 1. 3M Levered Beta is 1.15 2. Risk free rate is 4.00% 3. Equity risk premium is 5.50% 4. Calculate cost of equity using CAPM: Risk-free rate + Beta*Equity Risk Premium 5. Implied Return = SOLV Net Income/Purchase Price Paid 6. Assume Spread is calculated by Implied Return - WACC 7. For PF WACC, use 3M's existing cost of debt from Scenario 1 and assume the incremental acquisition debt carries a 10.00% interest rate (consistent with Scenario 1 assumptions). Print the output here. Format all final percentages to two decimal places.

Solventum (SOLV) announced a $2.0 billion strategic expansion funded with 70% debt and 30% equity, which caused its share price to increase by 5% relative to the closing price on 11/18/2025. Using the most recent accretion/dilution model rerun scenario 1, assuming the updated SOLV share price. Determine the revised premium 3M would pay under the updated assumptions to keep EPS accretion flat relative to the level from the original 30% premium case. Write back to me with what I requested. In the output, round the percentage to two decimal places.

In the Accretion / Dilution Model, assume stock-based compensation equals 3% of the sum of operating expenses and cost of goods sold, calculated using the model’s existing methodology, and added back to free cash flow in each forecast year. Using the “DCF-Solv” tab, provide an updated estimate of the present value of forecast-period cash flows, excluding the terminal value, under the following assumptions: - Mid-year discounting - Revenue growth of 1.0% from FY2025E through the end of the forecast period Give me figures in USD millions, rounded to two decimal places. Reply right here.

In the Accretion / Dilution Model, there is an error in the calculation of Cost of Product and Cost of Software and Rentals. Calculate the correct revised implied Enterprise Value after the divestiture. Please fix the linking and use the correct formula in the "DCF-Solv Tab" to calculate Product Gross Margin and Software & Rentals Gross Margin to help with the next analysis: In the Accretion / Dilution Model, Solventum's Purification & Filtration Segment (P&F) is being divested at the end of 2025E / beginning of 2026E and should be reflected in financial projections in the "DCF-Solv" tab. The current assumptions in the model for the Purification & Filtration Segment are as follows: - Revenue Growth Rate: 2.0% annually after 2024A - Gross Margins: P&F Gross Margins constant since 2024A - Operating Expenses: P&F Opex % of Revenues constant since 2024A P&F's 2024A results can be in Solventum's 2024 Annual Report. Round financial figures to 2 decimal points, putting them in USD millions. Write a reply to me here with the requested value.

Using the 3Q 2025 3M 10Q and the accretion dilution model, calculate the following deliverables. Present all values in millions ($mm), number of shares in millions (mm), and round to whole numbers. For percentages, two decimal places. Give me the answer straight back here as a message. Base your deliverables on the following assumptions: - For the projections of 2026E cashflow available for buyback, use the extrapolation formulae (12/9 multiplication convention i.e multiply by 12/9) for specific income statement and cashflow items to convert them from nine-months ending September 2025 to full year January to December 2025. For clarity, Income statement and cashflow items on which extrapolation formulae is applied include revenue, operating expenses, depreciation & amortization, Net interest expense, Net income, cashflow from operations and CAPEX (considered as sale of property, plant and equipment). - Assume a growth rate of 5% across specific cashflow statement items calculated using extrapolation formulae for 2025E to calculate the projected cashflow statement items for the year 2026E. Consider CAPEX as sale of property, plant and equipment for the above calculation. Cashflow items on which 5% growth is applied include cashflow from operations and CAPEX. - Use 3M data in "Assumptions S2" tab for required data in the accretion dilution model for scenario 2. Calculate for me: 1. The free cash flow available for buy back in 2026E using the above assumptions by incorporating cashflow from operations and CAPEX in the formulae. 2. The buyback capacity of 3M using the Cashflow available for buy back in 2026E calculated above, minimum cash balance of $100 million, existing cash balance and proceeds from sale. 3. The number of shares that can be repurchased by 3M with this capacity. 4. The percentage reduction in shares outstanding of 3M if the company uses its entire capacity for a buyback.